IQVIA Holdings Inc. $IQV Shares Purchased by Swedbank AB

Key Points

• Swedbank AB increased its stake in IQVIA Holdings Inc. by 6.5%, acquiring an additional 5,669 shares, bringing its total to 92,551 shares valued at approximately $14.58 million.
• IQVIA's shares opened at $187.29, down 1.5%; the stock has a market cap of $31.84 billion and reported quarterly revenue of $4.02 billion, surpassing analysts' expectations.
• Analysts have a consensus rating of "Moderate Buy" for IQVIA, with a price target averaging $229.64, indicating positive sentiment toward the company's growth prospects.

Swedbank AB raised its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 6.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 92,551 shares of the medical research company's stock after buying an additional 5,669 shares during the quarter. Swedbank AB owned about 0.05% of IQVIA worth $14,585,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Canada Pension Plan Investment Board lifted its holdings in shares of IQVIA by 7.3% in the 1st quarter. Canada Pension Plan Investment Board now owns 4,594,831 shares of the medical research company's stock worth $810,069,000 after acquiring an additional 312,807 shares during the last quarter. JPMorgan Chase & Co. raised its position in IQVIA by 45.7% in the first quarter. JPMorgan Chase & Co. now owns 2,545,014 shares of the medical research company's stock valued at $448,686,000 after purchasing an additional 798,534 shares during the period. American Century Companies Inc. lifted its stake in IQVIA by 26.8% during the first quarter. American Century Companies Inc. now owns 1,438,995 shares of the medical research company's stock worth $253,695,000 after purchasing an additional 304,258 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of IQVIA by 2.9% during the first quarter. Dimensional Fund Advisors LP now owns 1,428,561 shares of the medical research company's stock worth $251,852,000 after buying an additional 40,699 shares during the period. Finally, Pacer Advisors Inc. raised its holdings in shares of IQVIA by 5,036.1% in the 1st quarter. Pacer Advisors Inc. now owns 871,704 shares of the medical research company's stock valued at $153,681,000 after buying an additional 854,732 shares during the period. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, insider Keriann Cherofsky sold 549 shares of the stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total transaction of $105,149.97. Following the sale, the insider owned 2,910 shares of the company's stock, valued at $557,352.30. This trade represents a 15.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Eric Sherbet sold 5,800 shares of the business's stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the completion of the transaction, the insider directly owned 27,178 shares of the company's stock, valued at $5,165,178.90. The trade was a 17.59% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

IQV has been the topic of several research reports. Mizuho increased their price target on shares of IQVIA from $190.00 to $225.00 and gave the stock an "outperform" rating in a research report on Friday, July 25th. Robert W. Baird upped their target price on shares of IQVIA from $159.00 to $196.00 and gave the stock a "neutral" rating in a research note on Wednesday, July 23rd. Redburn Partners set a $214.00 price target on shares of IQVIA in a research report on Wednesday, September 3rd. UBS Group upped their price objective on IQVIA from $185.00 to $225.00 and gave the stock a "buy" rating in a research report on Wednesday, July 23rd. Finally, Evercore ISI lifted their target price on IQVIA from $170.00 to $180.00 and gave the company an "outperform" rating in a report on Wednesday, July 9th. Eighteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $229.64.

IQVIA Price Performance

NYSE IQV traded down $0.58 during mid-day trading on Tuesday, hitting $187.25. The stock had a trading volume of 401,176 shares, compared to its average volume of 1,870,672. The company has a 50 day simple moving average of $185.35 and a 200 day simple moving average of $167.16. The company has a market cap of $31.83 billion, a price-to-earnings ratio of 27.12, a P/E/G ratio of 2.06 and a beta of 1.32. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $241.88. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.45.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, beating analysts' consensus estimates of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The business had revenue of $4.02 billion during the quarter, compared to analysts' expectations of $3.96 billion. During the same quarter last year, the business posted $2.64 earnings per share. The business's revenue for the quarter was up 5.3% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Equities analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.